These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 12928744)

  • 1. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
    Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
    Capuano C; Sesana M; Leonzi O; Cuccia C
    J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
    Moliterno DJ; Califf RM; Aguirre FV; Anderson K; Sigmon KN; Weisman HF; Topol EJ
    Am J Cardiol; 1995 Mar; 75(8):559-62. PubMed ID: 7887377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR; Pezzullo J; Mascelli MA; Frederick B; Kleiman NS; Freedman J
    Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors.
    Harjai KJ; Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Na Y; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Rutherford BD; Lansky AJ; Mehran R
    Am J Cardiol; 2007 Jan; 99(2):202-7. PubMed ID: 17223419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
    Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
    Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD
    Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ
    Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
    Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.